Global Antidiarrheal Drugs Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antidiarrheal Drugs Sales Market Report 2024
Market Analysis and InsightsGlobal Antidiarrheal Drugs Market
Antidiarrheal drugs are used to treat abrupt diarrhea and possess the mechanism of slowing down the movement of the gut and helps to diminish the number of bowel movements and also make the stools less watery. Distinct causes of diarrhea can be a virus such as a rotavirus, hepatitis, a bacterium such as E.coli, Shigella, and parasites causing amoebiasis and giardiasis. Majority of the events of diarrhea are recognized to be concluded with simple dietary modifications and may not require treatment, however, in certain cases of severe diarrhea, laboratory assessment is requisite which includes blood tests, and stool specimen evaluation to analyze the type of diarrhea.
Due to the COVID-19 pandemic, the global Antidiarrheal Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, OTC Drugs accounting for % of the Antidiarrheal Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Adults segment is altered to an % CAGR throughout this forecast period.
The United States Antidiarrheal Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Antidiarrheal Drugs include Johnson & Johnson, Novartis, GlaxoSmithKline, Proctor & Gamble, Pfizer, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Antidiarrheal Drugs Scope and Market Size
The global Antidiarrheal Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Antidiarrheal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
OTC Drugs
Prescription Drugs
Adults
Children
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Johnson & Johnson
Novartis
GlaxoSmithKline
Proctor & Gamble
Pfizer
Actelion
Perrigo
Lupin
Glenmark Pharmaceuticals
Sanofi Aventis
Merck & Co.
Bayer
Antidiarrheal drugs are used to treat abrupt diarrhea and possess the mechanism of slowing down the movement of the gut and helps to diminish the number of bowel movements and also make the stools less watery. Distinct causes of diarrhea can be a virus such as a rotavirus, hepatitis, a bacterium such as E.coli, Shigella, and parasites causing amoebiasis and giardiasis. Majority of the events of diarrhea are recognized to be concluded with simple dietary modifications and may not require treatment, however, in certain cases of severe diarrhea, laboratory assessment is requisite which includes blood tests, and stool specimen evaluation to analyze the type of diarrhea.
Due to the COVID-19 pandemic, the global Antidiarrheal Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, OTC Drugs accounting for % of the Antidiarrheal Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Adults segment is altered to an % CAGR throughout this forecast period.
The United States Antidiarrheal Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Antidiarrheal Drugs include Johnson & Johnson, Novartis, GlaxoSmithKline, Proctor & Gamble, Pfizer, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Antidiarrheal Drugs Scope and Market Size
The global Antidiarrheal Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Antidiarrheal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
OTC Drugs
Prescription Drugs
Segment by Application
Adults
Children
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Johnson & Johnson
Novartis
GlaxoSmithKline
Proctor & Gamble
Pfizer
Actelion
Perrigo
Lupin
Glenmark Pharmaceuticals
Sanofi Aventis
Merck & Co.
Bayer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices